--- title: "'Exercise in a Pill' Goes Mainstream: SLU-PP-332, 5-Amino-1MQ, and MOTS-c — and Why the FDA's July PCAC Vote Won't Cover All of Them — June 12, 2026 | PepTracker Pro Blog" description: "A wave of 'exercise mimetic' and mitochondrial metabolic compounds — SLU-PP-332, 5-Amino-1MQ, and MOTS-c — is moving from research-chemical forums into mainstream wellness, with anti-doping labs now building detection assays. But there's a critical distinction buyers miss: only some of these are on the FDA's July 23–24 PCAC compounding review list. We break down the mechanisms, the evidence (almost entirely preclinical), and what the July vote actually changes." lang: en json-ld: | [ { "@context": "https://schema.org", "@type": "Organization", "name": "PepTracker Pro", "url": "https://peptrackerpro.com", "logo": "https://peptrackerpro.com/favicon.png", "description": "Evidence-based educational resource dedicated to improving peptide research literacy.", "contactPoint": { "@type": "ContactPoint", "email": "hello@peptrackerpro.com", "contactType": "customer support" }, "sameAs": [] }, { "@context": "https://schema.org", "@type": "Article", "headline": "'Exercise in a Pill' Goes Mainstream: SLU-PP-332, 5-Amino-1MQ, and MOTS-c — and Why the FDA's July PCAC Vote Won't Cover All of Them — June 12, 2026", "description": "A wave of 'exercise mimetic' and mitochondrial metabolic compounds — SLU-PP-332, 5-Amino-1MQ, and MOTS-c — is moving from research-chemical forums into mainstream wellness, with anti-doping labs now building detection assays. But there's a critical distinction buyers miss: only some of these are on the FDA's July 23–24 PCAC compounding review list. We break down the mechanisms, the evidence (almost entirely preclinical), and what the July vote actually changes.", "datePublished": "2026-06-12", "dateModified": "2026-06-12", "author": { "@type": "Organization", "name": "PepTracker Pro Research Team", "url": "https://peptrackerpro.com" }, "publisher": { "@type": "Organization", "name": "PepTracker Pro", "logo": { "@type": "ImageObject", "url": "https://peptrackerpro.com/favicon.png" } }, "mainEntityOfPage": { "@type": "WebPage", "@id": "https://peptrackerpro.com/blog/exercise-mimetic-research-compounds-mainstream-slu-pp-332-5-amino-1mq-mots-c-pcac-june-12-2026" } }, { "@context": "https://schema.org", "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "Home", "item": "https://peptrackerpro.com" }, { "@type": "ListItem", "position": 2, "name": "Blog", "item": "https://peptrackerpro.com/blog" }, { "@type": "ListItem", "position": 3, "name": "'Exercise in a Pill' Goes Mainstream: SLU-PP-332, 5-Amino-1MQ, and MOTS-c — and Why the FDA's July PCAC Vote Won't Cover All of Them — June 12, 2026", "item": "https://peptrackerpro.com/blog/exercise-mimetic-research-compounds-mainstream-slu-pp-332-5-amino-1mq-mots-c-pcac-june-12-2026" } ] } ] --- [Skip to main content](#main) **Educational information only.** This site does not provide medical advice. [Read full disclaimer](/disclaimer) [PepTracker Pro](/) [Home](/)[Peptides](/peptides)[Compare](/compare)[Glossary](/glossary)[Blog](/blog)[Calculators](/calculators)[Start Here](/start) [Open the App](https://app.peptrackerpro.com) [Blog](/blog)/ 'Exercise in a Pill' Goes Mainstream: SLU-PP-332, 5-Amino-1MQ, and MOTS-c — and Why the FDA's July PCAC Vote Won't Cover All of Them — June 12, 2026 Research & Compounds Research & Compounds # 'Exercise in a Pill' Goes Mainstream: SLU-PP-332, 5-Amino-1MQ, and MOTS-c — and Why the FDA's July PCAC Vote Won't Cover All of Them — June 12, 2026 PepTracker Pro Research Team June 12, 2026 9 min read ## Table of Contents - [The 'Exercise in a Pill' Wave Hits the Mainstream](#section-0) - [SLU-PP-332: An ERR Agonist That Mimics Endurance Training](#section-1) - [5-Amino-1MQ and MOTS-c: Same Marketing Shelf, Different Mechanisms](#section-2) - [Why the July PCAC Vote Won't Cover All of Them](#section-3) - [What to Watch and How to Read the Evidence](#section-4) ## The 'Exercise in a Pill' Wave Hits the Mainstream This week STAT reported on a milestone that the peptide community has watched coming for two years: peptides and peptide-adjacent 'research compounds' are going mainstream, tracing how BPC-157 jumped from a Croatian lab to bodybuilding forums to the FDA's regulatory agenda. The same migration is now visible in a different corner of the market — metabolic and 'exercise mimetic' compounds that promise the benefits of training, fat loss, and longevity without an incretin drug's appetite suppression. Three names dominate the conversation in June 2026: SLU-PP-332, an ERR pan-agonist marketed as 'exercise in a pill'; 5-Amino-1MQ, an NNMT inhibitor sold for fat metabolism; and MOTS-c, a mitochondrial-derived peptide. All three are now offered direct-to-consumer through the same channels that sell GLP-1 analogs and healing peptides — and all three rest on almost entirely preclinical evidence. For consumers and clinicians, the most important fact is the one most often skipped: these compounds work through completely different mechanisms, sit in different regulatory buckets, and carry very different levels of human data. ## SLU-PP-332: An ERR Agonist That Mimics Endurance Training SLU-PP-332 is the newest of the three to gain real traction. It is a small-molecule pan-agonist of the estrogen-related receptors (ERRα, ERRβ, and ERRγ) — orphan nuclear receptors that act as master switches for mitochondrial biogenesis and oxidative metabolism. The 'SLU' in its name reflects its Saint Louis University origin, where it was first characterized by Thomas Burris and colleagues. In mice, SLU-PP-332 increased fast oxidative (Type IIa) muscle fibers, fatty-acid oxidation, and treadmill endurance in an ERRα-dependent way; in metabolic-syndrome models it raised energy expenditure and improved insulin sensitivity and reduced fat mass without the animals eating less. That mechanism is why it is marketed as an 'exercise mimetic.' Two cautions matter. First, despite the hype, there are no published human clinical trials of SLU-PP-332 as of June 2026 — every efficacy claim traces back to cell or rodent work. Second, and tellingly, anti-doping laboratories have already published methods to detect SLU-PP-332 and its metabolites. Detection assays don't get built for compounds nobody is using; they get built because athletes are already taking it. Critically, SLU-PP-332 is a small molecule, not a peptide, and it is not among the seven peptides the FDA will review for compounding in July — so no realistic regulatory pathway legitimizes it in the near term. ## 5-Amino-1MQ and MOTS-c: Same Marketing Shelf, Different Mechanisms It is easy to lump these compounds together because they share suppliers and a longevity-and-metabolism pitch, but they are mechanistically distinct. 5-Amino-1MQ is a small-molecule inhibitor of nicotinamide N-methyltransferase (NNMT); by blocking NNMT it is proposed to raise intracellular NAD+ (by up to ~40% in the foundational 2018 work) and shift fat cells toward energy expenditure. Like SLU-PP-332, it is not a peptide and has no completed large-scale human trials. MOTS-c, by contrast, is a genuine mitochondrial-derived peptide — a 16-amino-acid peptide encoded in mitochondrial DNA that regulates metabolic homeostasis and has been studied for obesity and osteoporosis-related endpoints. The practical takeaway for buyers: 'NAD+ booster,' 'exercise mimetic,' and 'mitochondrial peptide' are not interchangeable. They hit different targets (NNMT vs. ERR vs. mitochondrial signaling), and only one of the three — MOTS-c — is even a peptide. ## Why the July PCAC Vote Won't Cover All of Them The FDA's Pharmacy Compounding Advisory Committee (PCAC) meets July 23–24, 2026 to decide whether seven research peptides — BPC-157, TB-500, KPV, MOTS-c, Semax, Epitalon, and DSIP — should be added to the 503A Bulks List, the first potential regulatory green light for compounded research peptides in years. MOTS-c is on that list; a favorable vote could move it from gray-market 'research use only' status toward legitimate pharmacy compounding. But here is the distinction that gets lost in the excitement: SLU-PP-332 and 5-Amino-1MQ are NOT on the PCAC list. They are small molecules, not peptides, and they are not part of this review at all. Even a unanimous yes vote in July would do nothing to legitimize them. Buyers who assume 'the FDA is reviewing peptides in July, so these are about to be approved' are conflating three different regulatory categories — FDA-approved drugs, potentially-compoundable peptides under PCAC review, and unregulated research chemicals that no current process touches. The public comment docket (FDA-2025-N-6895) closes ahead of the meeting, and a second PCAC covering additional peptides is expected by early 2027. ## What to Watch and How to Read the Evidence For anyone tracking this space, three things are worth watching through the second half of 2026. First, human data: SLU-PP-332's entire case is preclinical, and the first credible human pharmacokinetic or safety study would meaningfully change its risk profile in either direction. Second, the muscle-preservation angle — as GLP-1 and amylin therapies drive large weight loss, lean-mass loss is a recognized problem, and ERR agonists are being discussed as a way to preserve oxidative muscle quality; whether that hypothesis survives contact with human trials is an open question. Third, the regulatory line: the July PCAC vote will sharpen, not blur, the divide between peptides on a compounding pathway (like MOTS-c) and research chemicals that remain outside any framework (like SLU-PP-332 and 5-Amino-1MQ). The recurring consumer-education point holds: provenance and evidence level are everything. A pharmacy-compounded peptide dispensed against a prescription and a vial of the same-named compound bought as a 'research chemical' are not the same product, and a compound being popular — even popular enough that anti-doping labs build tests for it — is not the same as a compound being proven safe in humans. Ready to track your peptide research? [Open PepTracker Pro](https://app.peptrackerpro.com) PepTracker Pro Research Team The PepTracker Pro Research Team is an editorial group of science writers, pharmacologists, and clinical researchers dedicated to making peptide science accessible. Every article is reviewed for accuracy against peer-reviewed sources and updated as new evidence emerges. ## Citations 1. \[1\] STAT — An obesity drug deep-dive, and peptides move mainstream (June 11, 2026) [Source](https://www.statnews.com/2026/06/11/an-obesity-drug-deep-dive-and-peptides-move-mainstream/) 2. \[2\] Billon C. et al. — A synthetic ERR agonist (SLU-PP-332) alleviates metabolic syndrome (ScienceDirect, 2024) [Source](https://www.sciencedirect.com/science/article/abs/pii/S0022356524171583) 3. \[3\] Chemical optimization of the exercise mimetic SLU-PP-332 — estrogen-related receptor signaling (PMC, 2026) [Source](https://pmc.ncbi.nlm.nih.gov/articles/PMC13112601/) 4. \[4\] In Vitro Metabolites of Exercise Mimetic SLU-PP-332 for Doping-Control Purposes (PubMed, 2026) [Source](https://pubmed.ncbi.nlm.nih.gov/41688415/) 5. \[5\] Neelakantan H. et al. — Selective small-molecule inhibitors of NNMT (5-Amino-1MQ), Biochem Pharmacol 2018 [Source](https://pubmed.ncbi.nlm.nih.gov/29514064/) 6. \[6\] FDA — July 23–24, 2026 Pharmacy Compounding Advisory Committee meeting [Source](https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026) 7. \[7\] FDA's Pep(tide) Rally! What Compounders and Industry Need to Know — FDA Law Blog [Source](https://www.thefdalawblog.com/2026/04/fdas-peptide-rally-what-compounders-and-industry-need-to-know-post-1-of-2/) **Disclaimer:** This article is for educational purposes only and does not constitute medical advice. Always consult a licensed healthcare provider. [Read full research disclaimer →](/research-disclaimer) ## Related Articles [![News & Updates cover image](/assets/blog-peptide-guides-BQE1jAYz.jpg)](/blog/fda-category2-removal-ll37-derivatives-dihexa-primate-pps-disease-modification-april-2026) News & Updates [ ### FDA Removes 12 Peptides from Category 2, LL-37 Derivative Breakthroughs, Dihexa Primate Data, and Pentosan Polysulfate Disease-Modification Evidence: April 26, 2026 ](/blog/fda-category2-removal-ll37-derivatives-dihexa-primate-pps-disease-modification-april-2026) The FDA formally removes 12 peptides from Category 2 ahead of July PCAC hearings, LL-37 derivative research achieves improved stability and efficacy, dihexa produces measurable synaptogenesis in non-human primates, pentosan polysulfate shows 6-month disease modification in OA, and DSIP fusion peptides cross the blood-brain barrier. PepTracker Pro Team April 26, 2026 9 min read fdacategory-2pcac [Read](/blog/fda-category2-removal-ll37-derivatives-dihexa-primate-pps-disease-modification-april-2026) [![News & Updates cover image](/assets/blog-peptide-guides-BQE1jAYz.jpg)](/blog/fda-pcac-july-peptides-tirzepatide-semaglutide-nejm-vk2735-vanquish-cap-gdf15-may-2026) News & Updates [ ### FDA PCAC July Lineup Confirmed for 7 Peptides, Tirzepatide Beats Semaglutide in NEJM Head-to-Head, VK2735 VANQUISH-2 Enrollment Completes, and CAP-GDF15 Opens New Appetite Pathway — May 8, 2026 Peptide Research Update ](/blog/fda-pcac-july-peptides-tirzepatide-semaglutide-nejm-vk2735-vanquish-cap-gdf15-may-2026) The FDA confirms its July 23–24 PCAC meeting will review BPC-157, TB-500, KPV, MOTS-c, Semax, Epithalon, and DSIP for 503A compounding eligibility. A landmark NEJM trial shows tirzepatide outperforms semaglutide by 6.5 percentage points in weight loss. Viking completes VANQUISH-2 enrollment for VK2735, and researchers identify CAP-GDF15 as a new appetite-suppressing peptide from the GDF15 propeptide region. PepTracker Pro Team May 8, 2026 8 min read FDAPCACBPC-157 [Read](/blog/fda-pcac-july-peptides-tirzepatide-semaglutide-nejm-vk2735-vanquish-cap-gdf15-may-2026) [![Policy & Pipeline cover image](/assets/blog-peptide-guides-BQE1jAYz.jpg)](/blog/telehealth-peptide-vertical-integration-noom-tailor-made-hims-eloralintide-tirzepatide-pcac-june-11-2026) Policy & Pipeline [ ### Telehealth Goes Vertical on Peptides: Noom Acquires Tailor Made Compounding, Hims & Hers Expands Production, and Eloralintide's Combination Era Begins — June 11, 2026 ](/blog/telehealth-peptide-vertical-integration-noom-tailor-made-hims-eloralintide-tirzepatide-pcac-june-11-2026) Telehealth platforms are racing to own regulated peptide supply chains ahead of the FDA's July 23–24 PCAC vote. Noom has acquired 503A pharmacy Tailor Made Compounding to add sermorelin and NAD+ to its formulary, following Hims & Hers' peptide facility purchase. Meanwhile, Eli Lilly's selective amylin agonist eloralintide enters its combination era with a tirzepatide pairing trial reading out late 2026. PepTracker Pro Team June 11, 2026 10 min read noomtailor made compoundinghims and hers [Read](/blog/telehealth-peptide-vertical-integration-noom-tailor-made-hims-eloralintide-tirzepatide-pcac-june-11-2026) [PepTracker Pro](/) Educational peptide information and research tracking tools. Not medical advice. #### Explore - [Peptide Directory](/peptides) - [Compare Peptides](/compare) - [Glossary](/glossary) - [Benefits](/benefits/sleep) #### Learn - [Blog](/blog) - [Calculators](/calculators) - [Start Here](/start) - [About](/about) #### Legal - [Editorial Policy](/editorial-policy) - [Research Disclaimer](/research-disclaimer) - [Disclaimer](/disclaimer) - [Privacy Policy](/privacy) - [Terms of Service](/terms) - [Contact](/contact) © 2026 PepTracker Pro. Educational purposes only. Not medical advice. Always consult a licensed healthcare provider.